A Clinical Prospective Study of Levonorgestrol releasing Intrauterine System in women with Abnormal Uterine Bleeding
European Journal of Molecular & Clinical Medicine,
2020, Volume 7, Issue 11, Pages 9168-9173
AbstractBackground: Levonorgestrel (LNG) releasing Intrauterine device (IUD) was first used in the USA in the year 2000. It contains 52 mg LNG mixed with polydimethylsiloxane that controls the rate of hormone release. Initially used for contraception has now been found to be effective in reducing heavy menstrual bleeding. This study tried to evaluate the effect of LNG-IUD on abnormal menstrual bleeding.
Methods: This prospective study was done in the Department of gynecology C.K.M G.M.H Hospital, Warangal. Treatments were performed in an outpatient setting during the first 10 days of the participant's menstrual cycle. Uterine cavity length was measured with a uterine sound before either of the treatment. The LNG-IUS was inserted as per the manufacturer's instructions.
Results: In this study n=54 patients were included with an age range from 30 to 49 years. The mean age was 43.5 years ± 2.5 years. PBAC (Pictorial blood loss assessment chart) was assessed at pre-treatment scores compared with post-treatment scores. Similarly, the QOL with standard format of (short 36) questionnaire was assessed at pre-treatment and post-treatment. The pre-treatment and post-treatment comparison revealed post-treatment significant improvement in patients treated with LNG-IUS.
Conclusion: The present study shows that the use of LNG-IUS for control of abnormal uterine bleeding results in significantly lowered blood loss over a period of 12 months follow-up. The treatment also results in higher levels of patient satisfaction, significant improvement in anemia, and improvement in overall quality of life scores.
- Article View: 157
- PDF Download: 72